Schedule of Cost of Goods sold

Square Pharmaceuticals Beximco Pharmaceuticals Renata Pharmaceuticals

Details
2021-2022 2020-2021 2021-2022 2020-2021 2021-2022 2020-2021

Revenue 57,59,79,41,359 50,70,30,28,902 34,66,91,72,052 29,49,35,73,869 31,07,05,54,548 29,97,07,01,575

Cost Of Goods Sold:

Materials Consumed 12,66,51,24,944 10,91,48,17,014 14,97,10,42,279 12,10,80,82,703 12,03,47,64,140 11,12,06,75,818
Direct labor 8,38,12,18,478 7,20,91,68,644 35,50,79,579 29,42,58,178 1,78,33,23,542 1,41,63,26,623
Manufacturing Overhead 7,37,43,04,792 6,83,61,33,924 4,90,85,72,206 3,95,85,32,311 3,21,69,39,700 2,82,04,38,209
Total Manufacturing Cost 28,42,06,48,214 24,96,01,19,582 20,23,46,94,064 16,36,08,73,192 17,03,50,27,382 15,35,74,40,650
Work-in-Process ( Opening ) 41,50,13,847 33,64,41,344 35,50,79,579 29,42,58,178 23,26,05,418 35,74,40,076
Work-in-Process (Closing) -44,60,12,445 -41,50,13,847 -68,48,08,447 -34,05,72,871 -45,13,79,546 -23,26,05,418

Cost of Goods manufactured 28,38,96,49,616 24,88,15,47,079 19,54,98,85,617 16,02,03,00,321 16,81,62,53,254 15,48,22,75,308

Finished Goods (Opening ) 2,11,83,62,474 2,03,68,50,950 1,80,39,30,326 1,12,87,28,172 1,73,99,66,965 1,55,91,02,590

Finished Goods (Closing) -2,54,99,85,110 -2,11,83,62,474 -2,48,62,92,696 -1,29,96,82,358 -2,26,53,63,191 -1,73,99,66,965
Cost of goods sold 27,95,80,26,980 24,80,00,35,555 18,85,49,19,733 15,57,00,71,581 16,34,45,82,496 15,78,70,75,979
Gross Margin 29,63,99,14,379 25,90,29,93,347 15,81,42,52,319 13,92,35,02,288 14,72,59,72,052 14,18,36,25,596
 Square Pharmaceuticals

• Leading pharmaceutical company

• Established in 1958
• Samson H Chowdhury ventured
Square Pharmaceuticals as a
partnership.
 Beximco Pharmaceuticals

• Leading pharmaceutical company

• Established in 1976
• Founded by Ahmed Sohail Fasihur
Rahman and Ahmed Salman
Fasiur Rahman
 Renata Pharmaceuticals

• 4th largest pharmaceutical company of

Bangladesh .
• Established in 1973.
• Syed S Kaiser Kabir ventured Renata
Pharmaceuticals.
 Discussion
Square Pharmaceuticals Beximco Pharmaceuticals Renata Pharmaceuticals

19.414
20.11
12.59
12.36

12.11
12.07
12.07

12.4
11.63

11.44
11.36
11.27
11.6

10.82

10.79

10.75

10.38
10.35
Materials Con- Direct Labor Manufacturing Work In Cost of goods Gross Margin
sumed Overhead process( Closing) sold

Square Phar- 11.6 11.63 10.79 10.75 11.27 11.44

maceuticals
Beximco 12.36 12.07 12.4 20.11 12.11 11.36
Pharmaceuti-
cals
Renata Phar- 10.82 12.07 12.59 19.414 10.35 10.38
maceuticals
 Recommendations

• All three companies should continue to focus on cost

optimization, especially in Materials Consumed, to
enhance cost efficiency.
• Careful management of work-in-process inventory is
crucial for Beximco Pharmaceuticals and Renata
Pharmaceuticals to avoid increased holding costs.
• Beximco Pharmaceuticals should evaluate its pricing
and operational efficiency to improve profitability.
• Square Pharmaceuticals should continue to focus on
cost efficiency and maintaining competitiveness in its
product pricing.